Amyotrophic Lateral Sclerosis (ALS)

Eighth Annual Tradition of Hope Gala Raises More Than $1.2 Million for MDA's Augie's Quest

ALS Briefs: NurOwn, Disease Modifiers, Biomarker Test

Eighth Annual Tradition Of Hope Gala To Support MDA's Augie's Quest

ALS Briefs: Neuralstem, Body Fat, Behavior, Respiratory Care

This roundup of recent amyotrophic lateral sclerosis (ALS) research and clinical trials news includes:

ALS Briefs: Diet, Autoimmune Disease, ALS TDI, Neuralstem, Cytokinetics

This roundup of recent amyotrophic lateral sclerosis (ALS) research and clinical trials news includes:

ALS Briefs: Protein Clumps, Cell-to-Cell Spread and More

This roundup of recent MDA-supported amyotrophic lateral sclerosis (ALS) research news and reviews includes:

UPDATE: FDA Approves Testing Multiple Sclerosis Drug in ALS

The U.S. Food and Drug Administration (FDA) has given the go-ahead to the nonprofit biotech ALS Therapy Development Institute (ALS TDI) to conduct a clinical trial of TDI132  — also known as fingolimod, or the brand name Gilenya— in people withALS (amyotrophic lateral sclerosis).

National ALS Biorepository Pilot Study Launched

ALS Briefs: Stem Cells, Risk Factors, Emotion Processing Abnormalities

This roundup of recent amyotrophic lateral sclerosis (ALS) research and clinical trials news includes:

MDA Study Reveals ‘Cost of Illness’ for ALS, DMD, MMD

"We now have numbers to point to," said Annie Kennedy, MDA's senior vice president of advocacy. "It's not just a back-of-the-envelope calculation anymore. It's real data."

Pages